



An Integrated Pharmaceutical Company
Focused on Natural Based Medicines

THC | CBD | PSILOCYBIN | CEPHARANTHINE | DMT

CORPORATE OVERVIEW

CSE:BUZZ March 2021

© 2006 The Authors
Journal compilation © 2006 Blackwell Publishing Ltd

The information contained in this presentation is confidential and shall be kept in strict confidence by you. You hereby agree that by accepting a copy of this presentation you will be deemed to have agreed to keep all information in this presentation strictly confidential and not to disclose, reproduce or transmit such information for any purpose whatsoever. Each person accepting this presentation hereby agrees to return it, along with any copies, promptly upon request. This presentation of Aura Health Inc. ("Aura" or the "Company") is for information only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. This presentation should not be construed as legal, financial or tax advice to any individual, as each individual's circumstances are different. Readers should consult with their own professional advisors regarding their particular circumstances. The Company makes no representation or warranty, express or implied, as to the accuracy or completeness of any information (whether communicated in written or oral form), other than this presentation, regarding the Company or its affiliates transmitted or made available to you. The Company expressly disclaims any and all liability relating to, or resulting from, the use of such other information which may be provided to you. Prospective investors are encouraged to conduct their own analysis and reviews of the company and of the information contained in this presentation and to carefully review and consider the various disclosures made by the Company in its reports filed on SEDAR (www.sedar.com). None of the Company's securities have been registered with or approved or disapproved by any Canadian provincial securities commission, by the U.S. Securities and Exchange Commission or by any state or foreign securities commission nor has any Canadian provincial securities commission, the U.S. Securities and Exchange Commission or any state or foreign securities commission reviewed or passed upon the accuracy or adequacy of this presentation. No independent person has confirmed the accuracy or truthfulness of the information contained in this presentation, nor whether it is complete. Any representation to the contrary is illegal. The securities being offered have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities laws. Any securities offered will be offered only to "accredited investors", as such term is defined under Regulation D and Regulation S under the U.S. Securities Act, respectively, and to persons in Canada who are "accredited investors" as defined under National Instrument 45-106 - Prospectus Exemptions on a private placement basis only. The information in this document is not targeted at the residents of any particular country or jurisdiction and is not intended for distribution to, or use by, any person in any jurisdiction or country where such distribution or use would be contrary to local law or regulation.

This presentation includes forward-looking information and forward-looking statements and information (collectively, "forward-looking information") within the meaning of applicable Canadian and U.S. securities laws. Statements containing the words "believe", "expect", "intend", "should", "seek", "anticipate", "will", "positioned", "project", "risk", "plan", "may", "estimate" or, in each case, their negative and words of similar meaning are intended to identify forward-looking information. Forward-looking information is based on currently available competitive, financial, and economic data and operating plans as of the date of this presentation, but are subject to known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements or industry results to be materially different from those expressed or implied by such forward-looking information. Such factors are based on information currently available to the Company, including information obtained from third party industry analysts and other third party sources, and are based on management's current expectations regarding future growth, results of operations, future capital (including the amount, nature and sources of funding thereof) and expenditures, the Company's anticipated business strategies, anticipated trends in the Company's business and anticipated market share and legalization in the cannabis industry. The Company can give no assurance that these estimates, expectations and projections will prove to have been correct. The forward-looking information contained in this presentation is expressly qualified by this cautionary statement. A number of risks, uncertainties and other factors could cause actual results to differ materially from the results discussed in the forward-looking information, including, but not limited to, the following: general industry and market conditions and growth rates; legislative and regulatory developments; general economic conditions and levels of economic activity including interest rate fluctuation; the Company has limited operating history in an emerging area of business and had negative cash flows from operations in its most recently completed financial year; adverse events relating to the Company's products could result in risks relating to product liability or other legal claims; risks related with reliance on key personnel; the Company's senior management has been key to its growth and the Company may be adversely affected if it is unable to retain them; conflicts of interest develop or the Company loses any key member of its senior management team; changes in employee relations; ability to enforce non-competition and other restrictive covenants in the Company's agreements; risks associated with implementation of growth initiatives; financing risks; lower than expected future revenues and profitability; the Company may face intense competition and expects competition to increase in the future, which could inhibit its development of customer base and generating revenue; the Company's ability to establish, maintain and defend intellectual property rights; changes to public perception of cannabis use; factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking information; general business, economic and competitive uncertainties; regulatory risks including risks related to the granting and expected timing of the approval of licenses and permits; ability to comply and the cost of compliance with changing regulations; risks related to criminal or civil sanctions in connection with failure to comply with regulations; risks associated with acquisitions and expansion; risks inherent in manufacturing operations; and other general risks of the cannabis industry as well as those risk factors disclosed elsewhere below. Such statements are based upon the current beliefs and expectations of the Company's management and are subject to significant business, social, economic, political, regulatory, competitive and other risks, uncertainties, contingencies and other factors. Many assumptions are based on factors and events that are not within the control of the Company. Actual future results may differ materially from historical results or current expectations. These risks, uncertainties and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. In addition, even if the outcome and financial effects of the plans and events described herein are consistent with the forward-looking information contained in this presentation, those results or developments may not be indicative of results or developments in subsequent periods. Although the Company has attempted to identify important risks and factors that could cause actual actions, events or results to differ materially from those described in forward-looking information, there may be other factors and risks that cause actions, events or results not to be as anticipated, estimated or intended. You should not place undue reliance on forward-looking information, which is based on the information available as of the date of this presentation. Forward-looking information contained in this presentation is as of the date of this presentation and, except as required by applicable law, the Company assumes no obligation to update or revise them to reflect new events or circumstances. Historical statements should not be taken as a representation that such trends will be replicated in the future. No statement in this presentation is intended to be nor may be construed as a profit forecast. To the extent any forward-looking information in this presentation constitutes "future-oriented financial information" or "financial outlooks" within the meaning of applicable Canadian securities laws, such information is being provided to demonstrate the anticipated market penetration and the reader is cautioned that this information may not be appropriate for any other purpose and the reader should not place undue reliance on such future-oriented financial information and financial outlooks. Future-oriented financial information and financial outlooks, as with forward-looking information generally, are, without limitation, based on the assumptions and subject to the risks set out above under the heading "Cautionary Statement Regarding Forward-Looking Information and Risk Factors". The Company's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Company's revenue and expenses may differ materially from the revenue and expenses profiles provided in this presentation. Such information is presented for illustrative purposes only and may not be an indication of the Company's actual

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines

Pharmadrug Product GmbH

EU Narcotics License with GMP
CBD & THC

Sairiyo Therapeutics Inc.

Pharmaceutical R&D
Cepharanthine & DMT

Super Smart

Adult-Use Psychedelics Retail
Psychedelic Truffles & Functional Mushrooms

PHARMADRUG: CANNABIS



OVERVIEW

PharmaDrug is a licensed Schedule 1 Narcotics distributor with Euro GMP product registration



STRONG REVENUE BASE

Importing and distributing Bedrocan cannabis from the Netherlands to over 300 German pharmacies



STRONG REVENUE BASE

Distributing EU-GMP certified medical cannabis from a Canadian based multinational cannabis company

PHARMADRUG: CANNABIS



Finalizing PharmaDrug's own branded strain from Eve and Co.'s offerings



Advanced discussions with other players to carry white label products



Active discussion with other sources of flower and oil (Portugal, Spain, Denmark and Australia)


PHARMADRUG: PSYCHEDELICS

Germany's Federal Institute of Drugs and Medical Devices (BfArM) recently approved a study on the use of Psilocybin in Treatment-Resistant Depression, further demonstrating the broadening acceptance towards psychedelics.

If Germany legalizes medical use of psilocybin, PharmaDrug will be able to capitalize on this with its adult use psilocybin operations in the Netherlands, coupled with the German medical cannabis distribution business.

PharmaDrug holds a Schedule 1 Narcotics Distribution License, enabling the importation of narcotics into Germany.

PharmaDrug also holds a Good Manufacturing Practice ("**GMP**") certification, enabling 3rd party manufacturing of narcotics under an in-house brand.




Medical psychedelics market ~
U\$100B and growing rapidly



Growing societal awareness and acceptance of
mental health disorders and addiction



Promising efficacy of psychedelics related to
mental & substance abuse disorders



Accelerated push for innovative
treatments using psychedelics



Sairiyo Therapeutics

**Pharmaceutical
Research &
Development**

SAIRIYO THERAPEUTICS: OVERVIEW

ACQUISITION OVERVIEW

- Sairiyo is a biotechnology company focused on repurposing and developing improved formulations of naturally derived compounds for serious, rare, and life-threatening diseases with the aim to obtain European Medicines Evaluation Agency and U.S. Food and Drug Administration ("**FDA**") approval.
- Advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases.

STRATEGIC RATIONALE

- Foundation for developing and commercializing controlled substances and naturally-derived medicines in Europe
- Expanding opportunities with an FDA focused strategy leveraging Sairiyo's expertise in the discovery and development of novel uses and reformulations of naturally-derived compounds for significant clinical unmet needs
- Paves the way for PharmaDrug to become a fully-integrated specialty pharmaceutical company




SAIRIYO THERAPEUTICS: VALUE PROPOSITION

- Developing Cepharanthine for serious rare and life-threatening diseases
- Peer-reviewed research for cancer, inflammatory and infectious diseases
- FDA Phase 1/2 clinical trial ready
- Strong Intellectual Property Portfolio
- Experienced Team and Strategic Relationships
- Significant Big Pharma Deals and Validated Drug comparisons
- Multiple Near-term Value Creation Catalysts




SAIRIYO THERAPEUTICS: 2021 CEPHARANTHINE STRATEGY



SAIRIYO THERAPEUTICS: DRUG R&D

Pharmaceutical Psychedelic Research: DMT Overview



DMT



Dimethyltryptamine “DMT” has been shown to improve ischemic brain injury in rats during pre-clinical research



DMT decreases brain lesion volume and improves subsequent motor function recovery



Orphan Status from the FDA. Provides DMT numerous benefits including tax credits, seven years of marketing exclusivity post regulatory approval, and others.



SAIRIYO THERAPEUTICS

Pharmaceutical Psychedelic Research: DMT Overview



Expanding product pipeline
through licensing



Development of novel uses
and delivery systems



Focus on pre-clinical and
clinical research



Research collaborations
with academic institutions
and industry



Adding medical, clinical
experts to its scientific
advisory board



Broadening intellectual
property portfolio with
unique formulations





Retail of Adult Use Psychedelic Truffles and Functional Mushrooms

SUPER SMART: RETAIL PSYCHEDELICS OVERVIEW



Super Smart is uniquely positioned to capitalize on the opportunity presented by the burgeoning psychedelics industry through its innovative retail brand concept: *SlimWinkel*.



Growing collection of “smart shops” operating under the brand SlimWinkel. Owned by Super Smart.

First psychedelic retail store purchased in Teil, Netherlands. SlimWinkel stores stand apart through their consistent design, open and inviting layout, knowledgeable staff, and high-quality selection

Set to launch a unique and innovative e-commerce channel

Opening of a flagship store in Amsterdam in early 2021, followed by opening retail locations in 5 other cities in the Netherlands



SLIM WINKEL: RETAIL PSYCHEDELICS

RETAIL STRATEGY



The SlimWinkel brand and retail concept will be used for physical locations, the e-commerce platform, and white label products

THOUGHT LEADERSHIP



SlimWinkel is a thought leader, innovator, and influencer in the burgeoning psychedelic space, providing content on how to microdose, which products to use, and bridging the gap between the adult- use, health & wellness, and medical market segments



SLIM WINKEL: RETAIL PSYCHEDELICS



Current Operations: Brick & Mortar and Ecommerce

SlimWinkel to launch a unique e-commerce platform in early 2021 with a differentiated product line and enhanced brand positioning

Enables SlimWinkel to capture market share quickly and establish greater brand recognition

The channel will sell psilocybin truffles, functional mushrooms, and other legal wellness plants within the Netherlands

The e-commerce platform will also be available outside of the Netherlands where it will not include psilocybin truffles



Acquired first smartshop located in Tiel, Netherlands in Oct 2020



Tiel location is a platform to build out and refine the retail business model for psychedelics



SLIM WINKEL: RETAIL PSYCHEDELICS

Growth & Trajectory



Timing: Retail to start at the end of Q1 2021

Dutch Market Penetration Objective: 10 retail stores across the country within by mid 2022

- Two Tier 1 stores in Amsterdam
- Five Tier 2 stores – The Hague, Maastricht, Rotterdam, Utrecht, and Nijmegen
- Three Tier 3 stores – Groningen, Eindhoven, Tiel



Narrowed search for a flagship superstore for SlimWinkel's new retail concept in Amsterdam

Flagship store to be a destination spot for tourists, will have enhanced and differentiated products for Dutch consumers

Identified 7 target cities where it intends to establish additional SlimWinkel stores



SUPER SMART: TRACTION & MILESTONES



MANAGEMENT TEAM



Daniel Cohen, CFA
CEO

Daniel has over 20 years of capital markets experience, most recently spending several years as Head of Sales at Beacon Securities. During this time, Daniel successfully financed and launched multiple public companies.



Harry Resin
President, Super Smart

Harry has worked in the cannabis industry for the last 17 years as a supply chain consultant to coffee shops in Amsterdam and as a founding member of an original Amsterdam seed company. He has also served as a staff writer for High Times.



Keith Li, CPA
CFO

Keith has over 10 years of experience in public accounting and accounting in the private sector. His specialties include audit and assurance, corporate accounting, financial reporting, and regulatory compliance services.

SCIENTIFIC ADVISORY BOARD



Terry Booth

Global cannabis industry pioneer and founder of Aurora Cannabis (TSX-ACB), Mr. Booth will chair PharmaDrug's Advisory Board and help guide the Company's European cannabis and psychedelics strategies.

Mr. Booth brings over 25 years of experience in creating, growing and leading companies in highly regulated industries.

- Significant capital markets and M&A expertise.
- Deep knowledge of European cannabis markets.
- Prominent investor in the emerging psychedelics space.



Dr. Steven Barker

Dr Barker will lead the research and development initiatives of N,N-Dimethyltryptamine (DMT) for mental health, neurological, and inflammatory disorders at PharmaDrug.

He has been actively involved in the research of psychedelics, with a primary focus on DMT since 1976

Dr Barker also is professor emeritus at Louisiana State University

CAPITALIZATION SUMMARY

Common Shares	317.0M
ITM Warrants & Options	127.1M
\$0.9M Debentures Convertible at \$0.05 ¹	17.4M

Fully Diluted ITM Shares Outstanding	311.6M
---	---------------

Out-of-the-Money Warrants & Options	34.3M
--	--------------

Current Cash Position	~\$3.00M
------------------------------	-----------------

Marketable Securities	~\$1.00M
------------------------------	-----------------

All currency amounts in Canadian Dollars

¹ Each debenture is convertible into 1 unit at a conversion price of \$0.05. Each unit consists of one common share and one-half of one common share warrant exercisable at \$0.07.

CONTACT INFORMATION

Daniel Cohen
Chief Executive Officer

77 King Street West, Suite 2905,
Toronto, ON M5K 1H1

dcohen@pharmadrug.co

647-202-1824

pharmadrug.co

APPENDIX: CANNABIS IN EUROPE BY THE NUMBERS

Europe is forecast to have the world's largest legal and medical cannabis markets by 2023.

In the European Union (EU) and Norway, 23 million people, or nearly 7% of all 15 - 64 year-olds, use cannabis in the past year; of these, 3.6%, or 12 million, consumed cannabis in the past month.

≈123B

**Potential total market value by 2028
(medicinal and recreational cannabis).**

≈65B

Estimated value of European recreational market by 2028

≈2.3trillion

Total spent on healthcare each year

CANNABIS IN EUROPE: KEY TRENDS & TAKEAWAYS

2019 marked a turning point for European cannabis

Germany imported **6,714 kg** of medical cannabis in 2019, more than double the total for 2018

The German medical market is expected to be **3x** larger than Canada, including higher anticipated pricing through government reimbursement.

Visibility and public acceptance of cannabis continues to expand as new scientific discoveries increase understanding of potential health benefits.

New legislation in six countries setting the stage for continued momentum beyond 2020.

More than **€500m** invested in European cannabis businesses.

At this pace, Europe will be world's largest legal market by 2023 and, by 2028, have a potential total market value of **€123B**

OPPORTUNITIES

SIZE:

EU market estimated to be USD \$123B by 2028

SUPPLY:

Insufficient cultivation

GROWTH:

Or lack there of... just three grow licenses granted for 2021